Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Non-profit group's support helps Repligen win Pfizer deal for SMA drug

This article was originally published in Scrip

Executive Summary

Repligen has made progress in its recent shift away from drug development to focus on bioprocessing by licensing its Phase I spinal muscular atrophy (SMA) program to Pfizer for up to $70 million plus royalties, in a deal that validates the more than $13 million invested by the non-profit group Families of SMA (FSMA) in the small molecule enzyme inhibitor RG3039.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC019950

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel